Previous 10 | Next 10 |
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q3 2019 Earnings Call Oct 30, 2019 , 4:30 p.m. ET Operator Continue reading
AtriCure (NASDAQ: ATRC ): Q3 GAAP EPS of -$0.25 beats by $0.06 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...
AAPL , ACA , ACAD , ADTN , AGI , AGNC , AKS , ALEX , ALSN , APA , ARES , ATRC , AWK , AXTI , AZPN , BFAM , BLDP , BOOT , CACI , CATM , CERS , CF , CHDN , CHEF , CLI , CLR , CMPR , CNMD , CNXN , COLM , CONE , CREE , CRUS , CRY , CSGS , CTSH , CW , DDD , ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019. AtriCure will host a conference cal...
Thinly traded AtriCure ( ATRC +6.8% ) is up on average volume, a modest 200K shares, as JPMorgan steps in to defend the stock after yesterday's 10% selloff in apparent reaction to a bearish report from Culper Research . More news on: AtriCure, Inc., Healthcare stocks news, S...
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global Healthcare Conference in New York C...
Now China claims US broke the negotiation agreement The market futures plunge after China threatens retaliation. Then China backtracks, and the market goes back up. China claims the US broke the agreement; we say China did. Am I the only one who is bored with the whole nonsense? All I can ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...